Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Nine Positive Cases among the Passengers Returning from Accra, Kinshasa, Frankfurt and South Sudan

 
The Ministry of Public Health announces the following results of the tests that were administered to 760 passengers on board the flights to Lebanon and 11 passengers on board private jets, as part of the third phase of expat returns:
 
  • Four confirmed COVID-19 cases among the Lebanese on board the plane from Accra.
  • Three confirmed COVID-19 cases among the returnees from Kinshasa.
  • One infection on board of a flight from Frankfurt.
  • One infection on board of a private flight from South Sudan.
  • The tests administered to the passengers on board of flights from Paris, Milano, Madrid, and London came back negative.
The passengers whose test results returned positive will be transferred to the hospital. Those who tested negative are urged to strictly comply with home-quarantine, and they will be daily followed up by the ministry. Any person who shows symptoms will be sent to the hospital and retested.
    2
ATC Name B/G Ingredients Dosage Form Price
S01AA13 FUCITHALMIC VISCOUS B Fusidic acid - 10mg/g 1% Drops 443,468 L.L
G01AC05 FLUOMIZIN B Dequalinium chloride - 10mg 10mg Tablet 775,397 L.L
G01AF01 FLAGYL B Metronidazole - 500mg 500mg Ovule 249,955 L.L
R03BA05 FLIXOTIDE EVOHALER B Fluticasone propionate - 250mcg/actutaion 250mcg/actutaion Inhalation suspension 1,484,946 L.L
R03BA05 FLIXOTIDE EVOHALER B Fluticasone propionate - 125mcg/actuation 125mcg/actuation Inhalation suspension 802,274 L.L
R03BA05 FLIXOTIDE EVOHALER B Fluticasone propionate - 50mcg/actuation 50mcg/actuation Inhalation suspension 671,921 L.L
M02AA10 FASTUM B Ketoprofen - 2.5g/100g 2.5% Gel 177,387 L.L
M02AA10 FASTUM B Ketoprofen - 2.5g/100g 2.5% Gel 337,304 L.L
S01CA01 FRAKIDEX B Dexamethasone disodium phosphate - 0.1g/100g, Framycetin sulfate - 0.5g/100g Ointment 141,103 L.L
M02AA15 FLECTOR E.P TISSUGEL B Diclofenac (epolamine) - 1% 1% Patch 1,204,083 L.L
R03DX10 FASENRA B Benralizumab - 30mg 30mg Injectable solution L.L
C01BC04 FLECAINE B Flecainide acetate - 100mg 100mg Tablet, scored 878,873 L.L
D04AA13 FENISTIL B Dimethindene maleate - 1mg/g 1mg/g Gel 196,201 L.L
R03DX10 FASENRA B Benralizumab - 30mg 30mg Injectable solution 214,213,273 L.L
D06AX01 FUCIDIN B Fusidic acid - 20mg/g 2% Cream 259,362 L.L
D06AX01 FUCIDIN CREAM B Fusidic acid - 2% 2% Cream 491,846 L.L
D06AX01 FUCIDIN CREAM B Fusidic acid - 2% 2% Cream 345,368 L.L
D06AX01 FUCIDIN B Fusidic acid (sodium salt) - 20mg/g 2% Ointment 259,362 L.L
M05BA04 FOSAMAX 70MG ONCE WEEKLY B Alendronate - 70mg 70mg Tablet 1,988,887 L.L
R05CB01 FLUIMUCIL B N-acetylcysteine - 600mg 600mg Tablet, effervescent 567,102 L.L
D06AX01 FUCIDIN OINTMENT B Fusidic acid (sodium salt) - 2% 2% Ointment 491,846 L.L
D06AX01 FUCIDIN OINTMENT B Fusidic acid (sodium salt) - 2% 2% Ointment 345,368 L.L
R05CB01 FLUIMUCIL MUCOLYTIC B N-acetylcysteine - 2% 2% Syrup 595,322 L.L
B02BB01 FIBRYGA BioHuman Fibrinogen, human - 1g 1g Injectable powder for solution+solvent 40,915,563 L.L
B02BD03 FEIBA BioHuman Factor VIII Inhibitor bypassing fraction - 500IU 500U (50U/ml) Injectable powder for solution+solvent 40,480,699 L.L
B02BD03 FEIBA BioHuman Factor VIII Inhibitor bypassing fraction - 1000IU 1000U (50U/ml) Injectable powder for solution+solvent 79,869,612 L.L
G03GA04 FOSTIMON BioHuman Urofollitropin - 150IU 150IU Injectable lyophilised powder for solution+diluent 36,347,120 L.L
G03GA04 FOSTIMON BioHuman Urofollitropin - 75IU 75IU Injectable lyophilised powder for solution+diluent 15,744,000 L.L
A16AB04 FABRAZYME BioTech Agalsidase beta - 35mg 35mg Injectable powder for concentrate for solution L.L
A16AB04 FABRAZYME BioTech Agalsidase beta - 35mg 35mg Injectable powder for concentrate for solution 295,038,213 L.L
    2
Sitemap
© Copyrights reserved to Ministry of Public Health 2025